Business
MIMEDX Announces Launch of G4Derm® Plus
Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovativ
About this update from Mimedx Group, Inc
[{"type":"image","alt":"MiMedx Group, Inc","displaySize":"","headline":null,"caption":"MiMedx Group, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/68d7327cd549087791cd3ae0959a08d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/A_8LiXJ4iaWt895m1_VDRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OA--/https://media.zenfs.com/en/globenewswire.com/68d7327cd549087791cd3ae0959a08d8","width":300,"height":120},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/A_8LiXJ4iaWt895m1_VDRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OA--/https://media.zenfs.com/en/globenewswire.com/68d7327cd549087791cd3ae0959a08d8","width":300,"height":120}},"lazy":false},{"type":"text","content":"Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company’s Portfolio","length":89,"tagName":"p"},{"type":"text","content":"G4Derm Plus Added to Premier and Vizient GPO Agreements","length":55,"tagName":"p"},{"type":"text","content":"MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets.","length":433,"tagName":"p"},{"type":"text","content":"“This launch showcases our efforts to leverage our sizable commercial reach to expand solutions available to clinicians in the markets we serve,” said Eric Smith, MIMEDX SVP, Marketing & International. We are continuing to build a best-in-class portfolio to provide surgeons options for treating complex wounds. G4Derm Plus adds an innovative, 510(k)-cleared solution for advanced wound management to our portfolio, and we are excited to see how synthetics and other novel approaches continue to shape advancements in patient care.”","length":536,"tagName":"p"},{"type":"text","content":"John Lantis, M.D., Site-Chief and Professor of Surgery at the Mount Sinai West Hospital and Icahn School of Medicine, added, “G4Derm Plus is an exciting self-assembling peptide that we are bringing to patients as a cutting-edge regenerative therapy. These bio-compatible peptides organi...